Advertisement

Topics

ArQule Incorporated Company Profile

16:12 EDT 20th September 2017 | BioPortfolio

ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identification and optimizationof drug development candidates and agrochemicals. Using combinatorial chemistry, a modular building block approach to the development of compounds, structure-guided compound design, high speed parallel chemical synthesis and

information technology, the Company rapidly develops large, diverse collections of compounds that have the potential to be biologically active. To date, the Company has entered into collaborative arrangements with Abbott Laboratories, Monsanto Company, Amersham Pharmacia Biotech AB, Roche Bioscience, Solvay Duphar B.V., American Homes Products Corporation, Inc. and Sankyo Company, Ltd. and has formed joint discovery programs with many biotechnology companies.

Location

19 Presidential Way
Woburn
01801-5140
United States of America

Contact

Phone: 781 994 0300
Fax: 781-376-6019
Email: info@arqule.com


News Articles [25 Associated News Articles listed on BioPortfolio]

ArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies

WASHINGTON (dpa-AFX) - Biopharmaceutical company ArQule, Inc. (ARQL) announced Tuesday that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with...

ArQule begins dosing of ARQ 092 in Phase I/II trial for overgrowth diseases

US-based biopharmaceutical firm ArQule has begun dosing patients with ARQ 092 in a Phase I/II clinical trial to treat patients with rare overgrowth diseases.

ArQule Announces First Patient Dosed In Phase I Trial Of BTK Inhibitor, ARQ 531, For B-Cell Malignancies

Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient ...

CCA readout boosts ArQule shares

ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017. The Company will...

ArQule begins Phase I of ARQ 531 in B cell malignancies

ArQule reports more Phase II data for FGFR inhibitor ARQ 087

ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, wi...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

AERODYNAMIC PROPERTIES AND IN SILICO DEPOSITION OF MELOXICAM POTASSIUM INCORPORATED IN A CARRIER-FREE DPI PULMONARY SYSTEM.

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

Clinical Trials [0 Results]

None

Companies [38 Associated Companies listed on BioPortfolio]

ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum produ...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

ArQule Incorporated

ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identifi...

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

Pharmapraxis

Founded in 2008 by the Axis Biotec Brasil™ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....

More Information about "ArQule Incorporated" on BioPortfolio

We have published hundreds of ArQule Incorporated news stories on BioPortfolio along with dozens of ArQule Incorporated Clinical Trials and PubMed Articles about ArQule Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ArQule Incorporated Companies in our database. You can also find out about relevant ArQule Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record